Experimental gene injection aims to halt rare childhood blindness

NCT ID NCT05616793

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gene therapy called OPGx-001 for people with vision loss caused by LCA5 gene mutations. The treatment is a one-time injection under the retina. The goal is to see if it is safe and can slow or stop vision loss. The study involves 22 participants aged 4 and older.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LCA5 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

LCA5-related retinopathy Leber congenital amaurosis 5 retinal degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Retina Foundation of the Southwest

    RECRUITING

    Dallas, Texas, 75231, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pennsylvania Perelman School of Medicine

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact